Download PDF
Horm Metab Res 2008; 40(9): 640-644
DOI: 10.1055/s-0028-1083811
Review

© Georg Thieme Verlag KG Stuttgart · New York

Possible Molecular Mechanisms by which Angiotensin II Type 1 Receptor Blockers (ARBs) Prevent the Development of Atrial Fibrillation in Insulin Resistant Patients

S.-I. Yamagishi 1 , T. Matsui 1 , K. Nakamura 1
  • 1Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine, Kurume, Japan
Further Information

Publication History

received 19.03.2007

accepted 30.10.2007

Publication Date:
15 September 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Atrial fibrillation (AF) is the most common disorder of cardiac rhythm and is responsible for substantial morbidity and mortality in general population. A recent community-based observational study revealed that diabetes and/or hypertension were associated with the development of AF. However, there is no definite evidence to show that patients with type 1 diabetes have an increased risk for the development of AF. These findings suggest that hyperglycemia per se may not explain the positive association between diabetes and AF. Growing body of evidence supports the presence of insulin resistance as the fundamental pathophysiological disturbance responsible for the metabolic syndrome, a constellation of metabolic disorders such as hypertension, dyslipidemia, and obesity that raise the risk for diabetes mellitus and cardiovascular diseases. Further, several clinical trials have shown that the renin-angiotensin system (RAS) plays an important role in the pathogenesis of insulin resistance. These observations suggest that insulin resistance could account for the increased risk for AF in the patients with diabetes and/or hypertension and that the interruption of the RAS may be a promising therapeutic strategy for preventing the development of AF. In the first part of this paper, we review clinical studies to support the concept that angiotensin II type 1 receptor blockers (ARBs) could prevent the development of AF in insulin resistant patients and discuss the possible underlying mechanisms. In the second part, we discuss the potential utility of telmisartan, a unique ARB with peroxisome proliferator-activated receptor-γ (PPAR-γ)-modulating activity, for blocking the development of AF in patients with insulin resistance.

Key words

atrial fibrillation - angiotensin II type 1 receptor blockers - insulin resistance - oxidative stress - PPAR-γ

References

  • 1 Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.  Am J Cardiol. 1998;  82 2N-9N
    CrossrefPubMedGoogle Scholar
  • 2 Ferro JM. Atrial fibrillation and cardioembolic stroke.  Minerva Cardioangiol. 2004;  52 111-124
    PubMedGoogle Scholar
  • 3 Mehta NN, Greenspon AJ. Atrial fibrillation. Rhythm versus rate control.  Geriatrics. 2003;  58 39-44
    PubMedGoogle Scholar
  • 4 Ortgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community.  Diabetes Obes Metab. 2004;  6 367-374
    CrossrefPubMedGoogle Scholar
  • 5 Hauner H. Managing type 2 diabetes mellitus in patients with obesity.  Treat Endocrinol. 2004;  3 223-232
    CrossrefPubMedGoogle Scholar
  • 6 Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study.  Am J Med. 2005;  118 489-495
    CrossrefPubMedGoogle Scholar
  • 7 Cersosimo E, Defronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases.  Diabetes Metab Res Rev. 2006;  22 423-436
    CrossrefPubMedGoogle Scholar
  • 8 Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications.  Curr Mol Med. 2006;  6 501-514
    CrossrefPubMedGoogle Scholar
  • 9 Cooper ME, Tikellis C, Thomas MC. Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system.  J Hypertens. 2006;  24 ((Suppl)) S57-S63
    PubMedGoogle Scholar
  • 10 Giacchetti G, Sechi LA, Rilli S, Carey RM. The renin-angiotensin-aldosterone system, glucose metabolism and diabetes.  Trends Endocrinol Metab. 2005;  16 120-126
    CrossrefPubMedGoogle Scholar
  • 11 Sharma AM. The obese patient with diabetes mellitus: from research targets to treatment options.  Am J Med. 2006;  119 S17-S23
    PubMedGoogle Scholar
  • 12 Yamagishi S, Nakamura K, Jinnouchi Y, Takenaka K, Imaizumi T. Molecular mechanisms for vascular injury in the metabolic syndrome.  Drugs Exp Clin Res. 2005;  31 123-127
    PubMedGoogle Scholar
  • 13 Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.  Drugs. 2004;  64 2537-2565
    CrossrefPubMedGoogle Scholar
  • 14 Brenner BM, Cooper ME, Zeeuw D de, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. RENAAL Study Investigators . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.  N Engl J Med. 2001;  345 861-869
    CrossrefPubMedGoogle Scholar
  • 15 Granger CB, MacMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K. CHARM Investigators and Committees . Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.  Lancet. 2003;  362 772-776
    CrossrefPubMedGoogle Scholar
  • 16 Ball SG. Benefits of blood pressure reduction in diabetic patients.  J Hypertens. 2003;  21 S31-S36
    CrossrefPubMedGoogle Scholar
  • 17 Strazzullo P, Galletti F. Impact of the renin-angiotensin system on lipid and carbohydrate metabolism.  Curr Opin Nephrol Hypertens. 2004;  13 325-332
    CrossrefPubMedGoogle Scholar
  • 18 Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.  Hypertension. 2004;  43 993-1002
    CrossrefPubMedGoogle Scholar
  • 19 Yamagishi S, Nakamura K. Telmisartan, its potential therapeutic implications in cardiometabolic disorders.  Recent Patents Cardiovasc Drug Discovery. 2006;  1 79-83
    PubMedGoogle Scholar
  • 20 Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.  Circulation. 2004;  109 2054-2057
    CrossrefPubMedGoogle Scholar
  • 21 Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.  Med Hypothese. 2005;  64 476-478
    PubMedGoogle Scholar
  • 22 Yamagishi S, Takenaka K, Inoue H. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.  Med Hypothese. 2006;  66 118-120
    PubMedGoogle Scholar
  • 23 Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.  J Am Coll Cardiol. 2005;  45 1832-1839
    CrossrefPubMedGoogle Scholar
  • 24 Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes.  Am J Hypertens. 2005;  18 731-737
    CrossrefPubMedGoogle Scholar
  • 25 Rewers M, Zaccaro D, D’Agostino R, Haffner S, Saad MF, Selby JV, Bergman R, Savage P. Insulin Resistance Atherosclerosis Study Investigators . Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study.  Diabetes Care. 2004;  27 781-787
    CrossrefPubMedGoogle Scholar
  • 26 Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN. Val-HeFT Investigators . Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).  Am Heart J. 2005;  149 548-557
    CrossrefPubMedGoogle Scholar
  • 27 MacMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA. CHARM Investigators . Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.  Am Heart J. 2006;  151 985-991
    CrossrefPubMedGoogle Scholar
  • 28 Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.  J Am Coll Cardiol. 2005;  45 712-719
    CrossrefPubMedGoogle Scholar
  • 29 Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persist fibrillation: a prospective and randomized study.  Circulation. 2002;  106 331-336
    CrossrefPubMedGoogle Scholar
  • 30 Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM. The renin-angiotensin system: a therapeutic target in atrial fibrillation.  Pacing Clin Electrophysiol. 2006;  29 1006-1012
    CrossrefPubMedGoogle Scholar
  • 31 Gaspo R, Bosch RF, Talajic M, Nattel S. Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model.  Circulation. 1997;  95 4027-4035
    PubMedGoogle Scholar
  • 32 Yu WC, Chen SA, Lee SH, Tai CT, Feng AN, Kuo BI, Ding YA, Chang MS. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs.  Circulation. 1998;  97 2331-2337
    PubMedGoogle Scholar
  • 33 Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation.  Cir Res. 2000;  67 440-447
    PubMedGoogle Scholar
  • 34 Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation.  Circulation. 2000;  101 2612-2617
    PubMedGoogle Scholar
  • 35 Dilaveris P, Giannopoulos G, Synetos A, Stefanadis C. Heart rate lowering by inhibition of the pacemaker current: a new therapeutic perspective in cardiovascular disease.  Curr Drug Target Cardiovasc Hematol Disord. 2005;  5 387-403
    PubMedGoogle Scholar
  • 36 Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort.  Cir Res. 1999;  100 87-95
    CrossrefPubMedGoogle Scholar
  • 37 Eickels M van, Grohe C, Lobbert K, Stimpel M, Vetter H. Angiotensin converting enzyme inhibitors block mitogenic signalling pathways in rat cardiac fibroblasts.  Naunyn Schmiedebergs Arch Pharmacol. 1999;  359 394-399
    CrossrefPubMedGoogle Scholar
  • 38 Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.  J Am Coll Cardiol. 2000;  35 1669-1677
    CrossrefPubMedGoogle Scholar
  • 39 Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation.  J Am Coll Cardiol. 2003;  41 2197-2204
    CrossrefPubMedGoogle Scholar
  • 40 Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio inthe cell.  J Clin Invest. 1998;  101 1326-1342
    CrossrefPubMedGoogle Scholar
  • 41 Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.  Cardiovasc Res. 2003;  60 315-325
    CrossrefPubMedGoogle Scholar
  • 42 Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.  Int J Cardiol. 2007;  115 135-143
    CrossrefPubMedGoogle Scholar
  • 43 Carnes CA, Chung MK, Nakayama T, Nakayama H, Baliga RS, Piao S, Kanderian A, Pavia S, Hamlin RL, MacCarthy PM, Bauer JA, Wagoner DR Van. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation.  Cir Res. 2001;  89 E32-E38
    CrossrefPubMedGoogle Scholar
  • 44 Dudley Jr SC, Hoch NE, MacCann LA, Honeycutt C, Diamandopoulos L, Fukai T, Harrison DG, Dikalov SI, Langberg J. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases.  Circulation. 2005;  112 1266-1273
    CrossrefPubMedGoogle Scholar
  • 45 Deroubaix E, Folliguet T, Rucker-Martin C, Dinanian S, Boixel C, Validire P, Daniel P, Capderou A, Hatem SN. Moderate and chronic hemodynamic overload of sheep atria induces reversible cellular electrophysiologic abnormalities and atrial vulnerability.  J Am Coll Cardiol. 2004;  44 1918-1926
    CrossrefPubMedGoogle Scholar
  • 46 Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long- standing persistent atrial fibrillation. Results of a prospective and controlled study.  Eur Heart J. 2003;  24 2090-2098
    CrossrefPubMedGoogle Scholar
  • 47 Kakuta H, Sudoh K, Sasamata M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.  Int J Clin Pharm Res. 2005;  25 41-46
    PubMedGoogle Scholar
  • 48 Hosono T, Mizuguchi H, Katayama K, Koizumi N, Kawabata K, Yamaguchi T, Nakagawa S, Watanabe Y, Mayumi T, Hayakawa T. RNA interference of PPARgamma using fiber-modified adenovirus vector efficiently suppresses preadipocyte-to-adipocyte differentiation in 3T3-L1 cells.  Gene. 2005;  348 157-165
    CrossrefPubMedGoogle Scholar
  • 49 Rosen ED. The transcriptional basis of adipocyte development.  Prostaglandins Leukot Essent Fatty Acids. 2005;  73 31-34
    CrossrefPubMedGoogle Scholar
  • 50 Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.  Curr Pharm Des. 2004;  10 2779-2286
    CrossrefPubMedGoogle Scholar
  • 51 Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.  Cir Res. 2004;  94 1168-1178
    CrossrefPubMedGoogle Scholar
  • 52 Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders.  Curr Mol Med. 2007;  7 463-469
    CrossrefPubMedGoogle Scholar
  • 53 Nagel JM, Tietz AB, Goke B, Parhofer KG. The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects.  Metabolism. 2006;  55 1149-1154
    CrossrefPubMedGoogle Scholar
  • 54 Benndorf RA, Rudolph T, Appel D, Schwedhelm E, Maas R, Schulze F, Silberhorn E, Boger RH. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.  Metabolism. 2006;  55 1159-1164
    CrossrefPubMedGoogle Scholar
  • 55 Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.  Diabetes Care. 2005;  28 757-758
    CrossrefPubMedGoogle Scholar
  • 56 Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.  Cardiovasc Diabetol. 2005;  4 6
    CrossrefPubMedGoogle Scholar
  • 57 Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease.  Diabetes Care. 2004;  27 1015
    PubMedGoogle Scholar
  • 58 Zimmermann M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.  Expert Opin Pharmacother. 2004;  5 1201-1208
    CrossrefPubMedGoogle Scholar

Correspondence

S.-I. YamagishiMD, PhD 

Department of Medicine

Division of Cardiovascular Medicine

Kurume University School of Medicine

Kurume 830-0011

Japan

Phone: +81/942/31 75 80

Fax: +81/942/31 77 07

Email: shoichi@med.kurume-u.ac.jp

      >